1. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584?586
2. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183?187
3. Meyer UA, Skoda RC, Zanger UM (1992) The genetic polymorphism of debrisoquine/sparteine metabolism ? clinical aspects. In: Kalow W (ed) International Encyclopedia of Pharmacology and Therapeutics, Section 137: Pharmocogenetics of drug metabolism. Pergamon Press, New York Oxford, pp 609?623
4. Eichelbaum M, Gross AS (1992) The genetic polymorphism of debrisoquine/sparteine metabolism ? clinical aspects. In: Kalow W (ed) International Encyclopedia of Pharmacology and Therapeutics, Section 137: Pharmocogenetics of drug metabolism. Pergamon Press, New York Oxford, pp 625?648
5. Alvan G, von Bahr C, Seideman P, Sjoqvist F (1982) High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet II: 333